Early clinical studies have confirmed first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) as the standard for first-line treatment of advanced NSCLC patients with EGFR-sensitive mutations, with the progression-free survival (PFS) ranging from 8 to 13.8 months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.